Monitoring Patients

In our cohort, we routinely measure:

A full blood count – to detect polycythaemia

A renal profile – to detect early strain on the renal system or early CKD

Liver function tests – to detect early liver inflammation or liver damage

Thyroid function testsif patients have used thyroid hormones in abuse

A lipid panel – to ascertain if lipid dysfunction is occurring with use.  Particularly suppressed LDL

An ECG – to monitor for cardiac hypertrophy changes

We recommend these are done a minimum of 6 monthly.  Ideally 3 monthly in very high risk users, eg, those not taking a break from use or having high risk behaviour, multiple IPEDS, especially multiple forms or AAS

All patients with ECG changes should be referred for echocardiography or cardiology assessment